The use of ACE inhibitors in patients with congestive cardiac failure is also increasing due to their beneficial effects on symptomatology and a reduction in mortality.7 However, hypotension may be a problem, particularly with enalapril,8 with the potential for myocardial ischaemia and this again may also be increased during induction of anaesthesia. Compared with other vasodilators, ACE inhibitors are more likely to be associated with hypoperfusion9 particularly so when their use is preceded by a diuretic. This compounds the fact-that they are, in any case, less likely to retain fluid and could conceivably increase the magnitude of the reduction of blood pressure that may occur at induction ofanaesthesia. The blood volume is relatively reduced when these patients are compared with those treated with other vasodilators. Hypotension with captopril has been shown to be more likely if the patient is sodium and volume depleted'" and therefore prolonged fasting before elective anaesthesia may increase the incidence of hypotension.
In conclusion, although ACE inhibitors are therapeutically effective, their widespread use may contribute to anaesthetic problems (and possibly to anaesthetic morbidity and mortality) unless anaesthetists are familiar with their actions. Studies are needed to define exactly their effects during the perioperative period but none of these has yet been published. It is to be hoped that after careful examination and with increasing experience, these agents may be demonstrated to be safe and even specifically indicated for patients with hypertension or congestive cardiac failure undergoing general anaesthesia. In the meantime we suggest that anaesthetists should be cautious and echo a recent leading article in the Lancet and urge doctors to 'view new developments critically'."' anaesthesia. 
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